Benzinga's Top Pre-Market Gainers
Horizon Pharma (NASDAQ: HZNP) moved up 16.63% to $2.80 in the pre-market session. Horizon Pharma will receive approval of DUEXIS from the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA).
Halozyme Therapeutics (NASDAQ: HALO) surged 14.86% to $6.34 in the pre-market session. Halozyme Therapeutics and Pfizer (NYSE: PFE) entered into a worldwide Collaboration for the purpose of developing and commercializing subcutaneous biologics using recombinant human hyaluronidase.
Red Hat (NYSE: RHT) soared 5.49% to $55.50 in the pre-market trading. Red Hat posted better-than-expected third-quarter revenue and announced its plans to buy privately held ManageIQ for $104 million in cash.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.